Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee, 57683-57684 [2022-20416]

Download as PDF khammond on DSKJM1Z7X2PROD with NOTICES Federal Register / Vol. 87, No. 182 / Wednesday, September 21, 2022 / Notices • Hand Delivery/Courier: Same as Mail above. All comments must be submitted in English, or if not, accompanied by an English translation. Comments submitted to the Commission should include only information that you wish to make available publicly. If you wish the Commission to consider information that you believe is exempt from disclosure under the Freedom of Information Act, a petition for confidential treatment of the exempt information may be submitted according to the procedures established in § 145.9 of the Commission’s regulations.1 The Commission reserves the right, but shall have no obligation, to review, prescreen, filter, redact, refuse or remove any or all of your submission from https://www.cftc.gov that it may deem to be inappropriate for publication, such as obscene language. All submissions that have been redacted or removed that contain comments on the merits of the ICR will be retained in the public comment file and will be considered as required under the Administrative Procedure Act and other applicable laws, and may be accessible under the Freedom of Information Act. FOR FURTHER INFORMATION CONTACT: Roger Smith, Associate Chief Counsel, Division of Market Oversight, Commodity Futures Trading Commission, (202) 418–5344; email: RSmith@CFTC.gov, or Rebecca Mersand, Paralegal Specialist, Division of Market Oversight, Commodity Futures Trading Commission, 202–941–8910; email: RMersand@CFTC.gov, and refer to OMB Control No. 3038–0099. SUPPLEMENTARY INFORMATION: Title: Process for a Swap Execution Facility or Designated Contract Market to Make a Swap Available to Trade (OMB Control No. 3038–0099). This is a request for extension of a currently approved information collection. Abstract: The collection of information is needed to help determine which swaps should be subject to the trade execution requirement under section 2(h)(8) of the Commodity Exchange Act pursuant to section 723 of the Dodd-Frank Wall Street Reform and Consumer Protection Act. A SEF or DCM that submits a determination that a swap is available to trade must address at least one of several factors to demonstrate that the swap is suitable for trading pursuant to the trade execution requirement. The Commission uses the collection of information to facilitate the application of the trade execution requirement and the requirements 1 17 CFR 145.9. VerDate Sep<11>2014 19:54 Sep 20, 2022 Jkt 256001 associated with methods of execution under parts 37 and 38 of the Commission’s regulations. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. On July 13, 2022, the Commission published in the Federal Register notice of the proposed extension of this information collection and provided 60 days for public comment on the proposed extension, 87 FR 41674 (60-Day Notice). The Commission did not receive any substantive comments on the 60-Day Notice. Burden Statement: The Commission estimates the burden of reviewing the prescribed factors and data to make a determination for this collection to be 16 hours per response. Respondents/Affected Entities: SEFs, DCMs. Estimated Number of Respondents: 5. Estimated Average Burden Hours per Respondent: 16. Estimated Total Annual Burden Hours: 80. Frequency of Collection: On occasion. There are no capital costs or operating and maintenance costs associated with this collection. (Authority: 44 U.S.C. 3501 et seq.) Dated: September 16, 2022. Robert Sidman, Deputy Secretary of the Commission. [FR Doc. 2022–20465 Filed 9–20–22; 8:45 am] BILLING CODE 6351–01–P DEPARTMENT OF DEFENSE Office of the Secretary Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee Under Secretary of Defense for Personnel and Readiness, Department of Defense (DoD). ACTION: Notice of Federal Advisory Committee meeting. AGENCY: The DoD is publishing this notice to announce that the following Federal Advisory Committee meeting of the Uniform Formulary Beneficiary Advisory Panel (UF BAP) will take place. SUMMARY: Open to the public Thursday, September 29, 2022, 10 a.m.–1 p.m. (eastern standard time). ADDRESSES: The meeting will be held telephonically or via conference call. The phone number for the remote access on September 29, 2022 is: CONUS: 1– DATES: PO 00000 Frm 00004 Fmt 4703 Sfmt 4703 57683 800–369–2046; OCONUS: 1–203–827– 7030; Participant Code: 8546285. These numbers and the dial-in instructions will also be posted on the UF BAP website at: https:// www.health.mil/Military-Health-Topics/ Access-Cost-Quality-and-Safety/ Pharmacy-Operations/BAP. FOR FURTHER INFORMATION CONTACT: Designated Federal Official (DFO) Colonel Paul J. Hoerner, USAF, 703– 681–2890 (voice), dha.ncr.j6.mbx.baprequests@mail.mil (email). Mailing address is 7700 Arlington Boulevard, Suite 5101, Falls Church, VA 22042–5101. Website: https:// www.health.mil/Military-Health-Topics/ Access-Cost-Quality-and-Safety/ Pharmacy-Operations/BAP. The most up-to-date changes to the meeting agenda can be found on the website. SUPPLEMENTARY INFORMATION: This meeting is being held under the provisions of the Federal Advisory Committee Act (FACA) of 1972 (5 U.S.C., Appendix, as amended), the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended), and 41 CFR 102–3.140 and 102–3.150. Due to circumstances beyond the control of the Designated Federal Officer, the Uniform Formulary Beneficiary Advisory Panel was unable to provide public notification required by 41 CFR 102–3.150(a) concerning its September 29, 2022 meeting. Accordingly, the Advisory Committee Management Officer for the Department of Defense, pursuant to 41 CFR 102– 3.150(b), waives the 15-calendar day notification requirement. Purpose of the Meeting: The Panel will review and comment on recommendations made to the Director, Defense Health Agency, by the Pharmacy and Therapeutics Committee, regarding the Uniform Formulary. Agenda: 1. 10:00 a.m.–10:10 a.m. Sign In for UF BAP members. 2. 10:10 a.m.–10:40 a.m. Welcome and Opening Remarks. a. Welcome, Opening Remarks, and Introduction of UF BAP Members by Col Paul J. Hoerner, DFO, UF BAP. b. Opening Remarks by UF BAP CoChair Senior Chief Petty Officer Jon R. Ostrowski, Non-Commissioned Officers Association. c. Introductory Remarks by Dr Edward Vonberg, Chief, Formulary Management Branch. d. Public Written Comments by Dr Edward VonBerg, Chief, Formulary Management Branch. 3. 10:40 a.m.–11:45 a.m. Scheduled Therapeutic Class Reviews. a. Overactive Bladder Agents—Beta 3 Adrenergic Agonists Subclass. E:\FR\FM\21SEN1.SGM 21SEN1 57684 Federal Register / Vol. 87, No. 182 / Wednesday, September 21, 2022 / Notices b. Antidepressants and Non-Opioid Pain Syndrome Agents—Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), NorepinephrineDopamine Reuptake Inhibitors (NDRIs), and Gamma-Aminobutyric Acid Analogs (GABAs) Subclasses. 4. 11:45 a.m.–12:30 p.m. Newly Approved Drugs Review. 5. 12:30 p.m.–12:45 p.m. Pertinent Utilization Management Issues. * Note that UF BAP discussion and vote will follow each section. 6. 12:45 p.m.–1:00 p.m. Closing remarks. a. Closing Remarks by UF BAP CoChair Senior Chief Petty Officer Jon R. Ostrowski. b. Closing Remarks by Col Paul J Hoerner, DFO, UF BAP. Meeting Accessibility: Pursuant to section 10(a)(1) of the FACA and 41 CFR 102–3.140 through 102–3.165, and subject to the availability of phone lines, this meeting is open to the public. Telephone lines are limited and available to the first 220 people dialing in. There will be 220 lines total: 200 domestic and 20 international, including leader lines. Written Statements: Pursuant to 41 CFR 102–3.140, and section 10(a)(3) of FACA, interested persons or organizations may submit written statements to the UF BAP about its mission and/or the agenda to be addressed in this public meeting. Written statements should be submitted to the UF BAP’s DFO. The DFO’s contact information can be found in the FOR FURTHER INFORMATION CONTACT section of this notice. Written comments or statements must be received by the UF BAP’s DFO at least five (5) calendar days prior to the meeting so they may be made available to the UF BAP for its consideration prior to the meeting. The DFO will review all submitted written statements and provide copies to UF BAP. Dated: September 16, 2022. Aaron T. Siegel, Alternate OSD Federal Register Liaison Officer, Department of Defense. [FR Doc. 2022–20416 Filed 9–20–22; 8:45 am] khammond on DSKJM1Z7X2PROD with NOTICES BILLING CODE 5001–06–P DEPARTMENT OF ENERGY DOE/Biological and Environmental Research Advisory Committee Office of Science, Department of Energy. ACTION: Notice of open virtual meeting. AGENCY: VerDate Sep<11>2014 19:54 Sep 20, 2022 Jkt 256001 This notice announces a meeting of the DOE Biological and Environmental Research Advisory Committee (BERAC). The Federal Advisory Committee Act requires that public notice of these meetings be announced in the Federal Register. DATES: Thursday, October 13, 2022; 11 a.m.–5:30 p.m. EDT, Friday, October 14, 2022; 11 a.m.–5:30 p.m. EDT. ADDRESSES: This meeting will be held digitally via webcast using Zoom. Instructions for Zoom, as well as any updates to meeting times or meeting agenda, can be found on the BERAC meeting website at: https:// science.osti.gov/ber/berac/Meetings. FOR FURTHER INFORMATION CONTACT: Dr. Tristram West, Designated Federal Officer, U.S. Department of Energy, Office of Science, Office of Biological and Environmental Research, SC–33/ Germantown Building, 1000 Independence Avenue SW, Washington, DC 20585–1290. Telephone: 301–903– 5155; fax (301) 903–5051 or email: tristram.west@science.doe.gov. SUPPLEMENTARY INFORMATION: Purpose of the Committee: To provide advice on a continuing basis to the Director, Office of Science of the Department of Energy, on the many complex scientific and technical issues that arise in the development and implementation of the Biological and Environmental Research Program. Tentative Agenda: • News from the Office of Biological and Environmental Research • News from the Biological Systems Science and Earth and Environmental Systems Sciences Divisions • Conclusions from the BERAC Subcommittee on International Benchmarking • Response to the BERAC Committee of Visitors on BSSD funding processes • Briefings from recent Workshops • BERAC business and discussion • Public comment Public Participation: The two-day meeting is open to the public. If you would like to file a written statement with the Committee, you may do so either before or after the meeting. If you would like to make oral statements regarding any of the items on the agenda, please send an email request to both Tristram West at tristram.west@ science.doe.gov and Andrew Flatness at andrew.flatness@science.doe.gov. You must make your request for an oral statement at least five business days before the meeting. Reasonable provision will be made to include the scheduled oral statements on the agenda. The Chairperson of the SUMMARY: PO 00000 Frm 00005 Fmt 4703 Sfmt 4703 Committee will conduct the meeting to facilitate the orderly conduct of business. Public comment will be limited to five minutes each. Minutes: The minutes of this meeting will be available for public review and copying within 45 days at the BERAC website: https://science.osti.gov/ber/ berac/Meetings/BERAC-Minutes. Signing Authority This document of the Department of Energy was signed on September 15, 2022, by Shena Kennerly, Acting Committee Management Officer, pursuant to delegated authority from the Secretary of Energy. That document with the original signature and date is maintained by DOE. For administrative purposes only, and in compliance with requirements of the Office of the Federal Register, the undersigned DOE Federal Register Liaison Officer has been authorized to sign and submit the document in electronic format for publication, as an official document of the Department of Energy. This administrative process in no way alters the legal effect of this document upon publication in the Federal Register. Signed in Washington, DC, on September 15, 2022. Treena V. Garrett, Federal Register Liaison Officer, U.S. Department of Energy. [FR Doc. 2022–20344 Filed 9–20–22; 8:45 am] BILLING CODE 6450–01–P DEPARTMENT OF ENERGY Federal Energy Regulatory Commission Combined Notice of Filings #1 Take notice that the Commission received the following electric rate filings: Docket Numbers: ER21–83–003. Applicants: Potomac Electric Power Company, PJM Interconnection, L.L.C. Description: Compliance filing: Potomac Electric Power Company submits tariff filing per 35: Potomac Electric Power Co. submits Compliance Filing in ER21–83 to be effective 1/1/ 2021. Filed Date: 9/15/22. Accession Number: 20220915–5170. Comment Date: 5 p.m. ET 10/6/22. Docket Numbers: ER22–2393–001. Applicants: Northern Indiana Public Service Company LLC. Description: Tariff Amendment: TDSIC WVPA CIAC Agreement to be effective 7/29/2022. Filed Date: 9/15/22. Accession Number: 20220915–5105. E:\FR\FM\21SEN1.SGM 21SEN1

Agencies

[Federal Register Volume 87, Number 182 (Wednesday, September 21, 2022)]
[Notices]
[Pages 57683-57684]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-20416]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Uniform Formulary Beneficiary Advisory Panel; Notice of Federal 
Advisory Committee

AGENCY: Under Secretary of Defense for Personnel and Readiness, 
Department of Defense (DoD).

ACTION: Notice of Federal Advisory Committee meeting.

-----------------------------------------------------------------------

SUMMARY: The DoD is publishing this notice to announce that the 
following Federal Advisory Committee meeting of the Uniform Formulary 
Beneficiary Advisory Panel (UF BAP) will take place.

DATES: Open to the public Thursday, September 29, 2022, 10 a.m.-1 p.m. 
(eastern standard time).

ADDRESSES: The meeting will be held telephonically or via conference 
call. The phone number for the remote access on September 29, 2022 is: 
CONUS: 1-800-369-2046; OCONUS: 1-203-827-7030; Participant Code: 
8546285.
    These numbers and the dial-in instructions will also be posted on 
the UF BAP website at: https://www.health.mil/Military-Health-Topics/Access-Cost-Quality-and-Safety/Pharmacy-Operations/BAP.

FOR FURTHER INFORMATION CONTACT: Designated Federal Official (DFO) 
Colonel Paul J. Hoerner, USAF, 703-681-2890 (voice), [email protected] (email). Mailing address is 7700 Arlington 
Boulevard, Suite 5101, Falls Church, VA 22042-5101. Website: https://www.health.mil/Military-Health-Topics/Access-Cost-Quality-and-Safety/Pharmacy-Operations/BAP. The most up-to-date changes to the meeting 
agenda can be found on the website.

SUPPLEMENTARY INFORMATION: This meeting is being held under the 
provisions of the Federal Advisory Committee Act (FACA) of 1972 (5 
U.S.C., Appendix, as amended), the Government in the Sunshine Act of 
1976 (5 U.S.C. 552b, as amended), and 41 CFR 102-3.140 and 102-3.150.
    Due to circumstances beyond the control of the Designated Federal 
Officer, the Uniform Formulary Beneficiary Advisory Panel was unable to 
provide public notification required by 41 CFR 102-3.150(a) concerning 
its September 29, 2022 meeting. Accordingly, the Advisory Committee 
Management Officer for the Department of Defense, pursuant to 41 CFR 
102-3.150(b), waives the 15-calendar day notification requirement.
    Purpose of the Meeting: The Panel will review and comment on 
recommendations made to the Director, Defense Health Agency, by the 
Pharmacy and Therapeutics Committee, regarding the Uniform Formulary.
    Agenda:
    1. 10:00 a.m.-10:10 a.m. Sign In for UF BAP members.
    2. 10:10 a.m.-10:40 a.m. Welcome and Opening Remarks.
    a. Welcome, Opening Remarks, and Introduction of UF BAP Members by 
Col Paul J. Hoerner, DFO, UF BAP.
    b. Opening Remarks by UF BAP Co-Chair Senior Chief Petty Officer 
Jon R. Ostrowski, Non-Commissioned Officers Association.
    c. Introductory Remarks by Dr Edward Vonberg, Chief, Formulary 
Management Branch.
    d. Public Written Comments by Dr Edward VonBerg, Chief, Formulary 
Management Branch.
    3. 10:40 a.m.-11:45 a.m. Scheduled Therapeutic Class Reviews.
    a. Overactive Bladder Agents--Beta 3 Adrenergic Agonists Subclass.

[[Page 57684]]

    b. Antidepressants and Non-Opioid Pain Syndrome Agents--Selective 
Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine 
Reuptake Inhibitors (SNRIs), Norepinephrine-Dopamine Reuptake 
Inhibitors (NDRIs), and Gamma-Aminobutyric Acid Analogs (GABAs) 
Subclasses.
    4. 11:45 a.m.-12:30 p.m. Newly Approved Drugs Review.
    5. 12:30 p.m.-12:45 p.m. Pertinent Utilization Management Issues.
    * Note that UF BAP discussion and vote will follow each section.
    6. 12:45 p.m.-1:00 p.m. Closing remarks.
    a. Closing Remarks by UF BAP Co-Chair Senior Chief Petty Officer 
Jon R. Ostrowski.
    b. Closing Remarks by Col Paul J Hoerner, DFO, UF BAP.
    Meeting Accessibility: Pursuant to section 10(a)(1) of the FACA and 
41 CFR 102-3.140 through 102-3.165, and subject to the availability of 
phone lines, this meeting is open to the public. Telephone lines are 
limited and available to the first 220 people dialing in. There will be 
220 lines total: 200 domestic and 20 international, including leader 
lines.
    Written Statements: Pursuant to 41 CFR 102-3.140, and section 
10(a)(3) of FACA, interested persons or organizations may submit 
written statements to the UF BAP about its mission and/or the agenda to 
be addressed in this public meeting. Written statements should be 
submitted to the UF BAP's DFO. The DFO's contact information can be 
found in the FOR FURTHER INFORMATION CONTACT section of this notice. 
Written comments or statements must be received by the UF BAP's DFO at 
least five (5) calendar days prior to the meeting so they may be made 
available to the UF BAP for its consideration prior to the meeting. The 
DFO will review all submitted written statements and provide copies to 
UF BAP.

    Dated: September 16, 2022.
Aaron T. Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2022-20416 Filed 9-20-22; 8:45 am]
BILLING CODE 5001-06-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.